尿激酶是一种纤溶酶原激活剂，临床上用于治疗血栓。
Urokinase, a human plasminogen activator, is used clinically to promote the dissolution of thrombi.
作者研究了血浆和组织激肽释放酶激活纤溶酶原的机制。
We studied the mechanism of plasma and tissue kallikrein in activating plasminogen.
为规模化快速纯化临床用高纯度纤溶酶原提供了新方法。
This method provided a new, fast and efficient method for large-scale purification of plasminogen for clinic use.
结论：糖尿病肾病患者存在血浆纤溶酶原激活物及其抑制物系统失衡。
Conclusion The diabetic nephropathy patients have imbalance of plasma plasminogen activator and its inhibitor system.
晚期6小时纤溶酶原激活剂没有减少梗死体积，而是更坏出血性转换。
Late 6-hour tPA did not decrease infarction but instead worsened hemorrhagic conversion.
纤溶酶原激活剂在血栓性疾病和出血性疾病的诊断具有潜在应用价值。
The potential application of PA as diagnostic tools in diseases of the thrombi.
目的观察应用重组组织型纤溶酶原激活剂溶栓治疗急性心肌梗死的效果。
Objective to observe the effect of recombinant tissue plasminogen activator in the treatment of acute myocardial infarction.
血浆纤溶酶原激活物抑制剂(PAI) - 1是纤溶系统的主要调控因子。
Plasminogen activator inhibitor-1 (PAI-1) is the main regulator of the fibrinolytic system.
对54例白血病患者进行血浆纤溶酶原(plg)及纤溶酶(PL)活性测定。
We measured the plasminogen (PLG) content and plasmin (pl) activity in 54 leukemic patients.
目的探讨急性冠状动脉综合征患者内皮组织纤溶酶原激活剂储备功能的变化规律。
Objective To study the changes of the endothelial tissue plasminogen activator reserve capacity in patients with acute coronary syndromes.
纤溶酶原和尿激酶前体的相互活化作用在纤溶的开始和加速上发挥着重要的作用。
Reciprocal activation of prourokinase and plasminogen is an important mechanism in the initiation and propagation of local fibrinolytic activity.
目的：探讨尿激酶型纤溶酶原激活因子的蛋白表达与上皮性卵巢癌生物学行为的关系。
Objective: To identify the significance of urokinase-type plasminogen activator expression in patients with epithelial ovarian carcinoma.
目的：研究重组纤溶酶原激活剂抑制剂-2基因表达对纤维肉瘤细胞超微结构的影响。
The effect of recombinant PAI-2 on the ultrastructure of fibrosarcoma-transplanted tumor was investigated in this study.
目的研究纤溶酶原激活物抑制剂(PAI1)与肝细胞癌(HCC)生物学特性的关系。
Objective to study the relationship between plasminogen activator inhibitor type 1 (PAI 1) and biological behaviour of hepatocellular carcinoma (HCC).
该酶具有强烈的纤溶活力和水解BAEE的活力，能直接作用纤维蛋白和间接激活纤溶酶原。
The enzyme showed strong fibrinolytic activity on fibrin and esterase activity in BAEE. It shows two effects, both acting on fibrin directly and activating plasminogen.
纤溶酶原激活物抑制剂1 (PAI - 1)是一种单链糖蛋白，起抑制纤溶活性的作用。
Plasminogen activator inhibitor-1 (PAI-1) is a single strand glycoprotein, which can inhibit plasminogen activation.
目的探讨纤溶酶原激活物抑制物-1（PAI- 1）启动子区基因多态性与脑卒中的关系。
Objective To investigate the relationship between the plasminogen activator inhibitor 1(PAI 1) promotor region gene polymorphism and cerebral stroke.
用酶联免疫吸附法检测血浆血管性假性血友病因子、凝血酶调节蛋白、纤溶酶原激活物抑制物1水平。
The von Willebrand's disease factors in plasm, adjusted protein of thrombase and inhibitor 1 of activator of plasminogen were detected with enzyme-linked immunosorbent assay.
以上结果说明，小鼠胚胎着床过程中胰蛋白酶及纤溶酶原激活因子等水解蛋白酶的活性起着重要作用。
These results suggested that proteolytic activities were involved in implantation, some proteinases such as trypsin and plasminogen activator had important functions during trophoblast invasion.
目的：观察小剂量长疗程尿纤溶酶原激活物(u - PA)治疗不稳定型心绞痛(uap)的临床疗效。
Objective: to investigate the clinical effectiveness of prolonged low-dose urine plasminogen activator (u-PA) therapy in patients with unstable angina pectoris (UAP).
方法采集42例急性脑梗死患者血浆，测定其纤维蛋白原、d二聚体及纤溶酶原含量，并与对照组进行比较。
Methods Collecting the plasma of 42 acute cerebral infarction patients, the content of fibrinogen? D dimer and fibrinolysin was determined, and was compared with their content in control group.
目的探讨缺血-再灌注对大鼠视网膜分泌组织型纤溶酶原激活物(TPA)的影响及其与视网膜水肿的关系。
Objective to explore the relationship between the activity change of tissue type plasminogen activator (TPA) of retinas and retinal edema in retinal ischemia and reperfusion rats.
目的以纤溶酶原、t - PA和PAI - 1为轴心，探讨纤溶系统对深静脉血栓形成(DVT)的影响。
Objective To investigate effects of fibrinolytic system upon deep venous thrombosis, focused on PLG, t-PA and PAI-1.
目的研究前炎症细胞因子对人胸膜间皮细胞（HPMC）释放纤溶酶原激活物抑制剂（PAI1）的诱导效应。
Objective To investigate effects of two proinflammatory cytokines on the production of plasminogen activator inhibitor 1(PAI 1) by human pleural mesothelial cells(HPMC).
目的观察罗格列酮对2型糖尿病患者血脂水平和血浆纤溶酶原激活物抑制剂1 (PAI - 1)活性的影响。
Objective To investigate the influence of rosiglitazone on blood lipids and plasma PAI-1 activity in type 2 diabetic patients.
为探讨纤溶酶原激活物抑制因子1（PAI 1）在肾损伤后纤维化中的作用和意义，揭示其发病的分子病理机制。
ObjectiveTo study the role and significance of plasminogen activator inhibitor-1(PAI-1) in renal fibrosis(RF) after damage and elucidate the molecular pathogenetic mechanisms of RF.
目的探讨血浆组织型纤溶酶原激活物(t -PA)及其抑制物(PAI - 1)在急性脑梗死发病中的意义。
Objective To assess the clinical significance of plasma t-PA, PAI-1 in acute cerebral infarction.
本文用尿激酶(UK)和人体组织型纤溶酶原激活剂(t - PA)进行了兔髂股动脉血栓实验性溶解的对照研究。
The thrombolytic effect was compared between urokinase (UK) and human tissue plasminogen activator (t-PA) in rabbits with experimental iliofemoral artery thrombus.
目的研究沙鼠脑缺血再灌注后脑内1型纤溶酶原激活物抑制剂(PAI - 1)蛋白表达变化，以及西比灵干预的影响。
Objective to study the effects of transient cerebral ischemic reperfusion (IR) and flunarizine on the expression of plasminogen activator inhibitor-1 (PAI-1) protein in brain tissue of gerbils.
目的研究沙鼠脑缺血再灌注后脑内1型纤溶酶原激活物抑制剂(PAI - 1)蛋白表达变化，以及西比灵干预的影响。
Objective to study the effects of transient cerebral ischemic reperfusion (IR) and flunarizine on the expression of plasminogen activator inhibitor-1 (PAI-1) protein in brain tissue of gerbils.
应用推荐